Published in Transplantation on June 15, 2004
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
Critical care issues in adult liver transplantation. Indian J Crit Care Med (2009) 0.88
Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol (2005) 0.88
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol (2013) 0.86
Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol (2006) 0.85
Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82
Recurrent hepatitis C after liver transplant. World J Gastroenterol (2014) 0.79
Metabolic syndrome after liver transplantation: preventable illness or common consequence? World J Gastroenterol (2012) 0.79
Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study. Biomed Res Int (2014) 0.78
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
C(2) monitoring: out of the blocks but with some way to go! Transplantation (2004) 0.75
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients. PLoS One (2015) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology (2003) 2.71
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl (2005) 2.35
Rabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. Arch Neurol (2005) 2.29
Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell (2013) 2.28
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology (2011) 2.25
HIV and syphilis prevalence among men who have sex with men: a cross-sectional survey of 61 cities in China. Clin Infect Dis (2013) 2.24
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg (2012) 2.18
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol (2005) 2.13
Pulmonary complications after elective liver transplantation-incidence, risk factors, and outcome. Transplantation (2012) 2.11
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl (2013) 2.03
Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg (2003) 2.03
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg (2003) 2.02
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol (2011) 1.99
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol (2008) 1.98
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol (2002) 1.85
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg (2009) 1.73
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol (2006) 1.72
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl (2008) 1.68
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? Liver Transpl (2007) 1.61
Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS (2011) 1.61
Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. J Hepatol (2010) 1.60
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology (2014) 1.58
Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol (2007) 1.56
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg (2009) 1.53
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53
Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol (2010) 1.49
The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood (2002) 1.49
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation (2004) 1.49
Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology (2008) 1.49
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (2008) 1.47
Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl (2013) 1.46
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol (2011) 1.46
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol (2010) 1.45
HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology (2003) 1.44
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. Transplantation (2006) 1.43
Feasibility and limits of split liver transplantation from pediatric donors: an italian multicenter experience. Ann Surg (2006) 1.43
Liver transplant-associated graft-versus-host disease. Transplantation (2003) 1.43
Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl (2004) 1.42
The histologic pattern of "biliary tract pathology" is accurate for the diagnosis of biliary complications. Am J Surg Pathol (2005) 1.42
Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transplant (2005) 1.41
Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol (2004) 1.41
Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol (2005) 1.41
Single shot of alemtuzumab as induction therapy after kidney transplantation is sufficient. Transpl Int (2011) 1.39
Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria. Liver Transpl (2015) 1.38
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Is portal hypertension a contraindication to hepatic resection? Ann Surg (2009) 1.34
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One (2009) 1.33
Current situation of donation after circulatory death in European countries. Transpl Int (2011) 1.32
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl (2006) 1.31
Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl (2007) 1.31
Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl (2008) 1.30
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology (2008) 1.30
Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int (2012) 1.30
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int (2011) 1.30
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant (2008) 1.29
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl (2008) 1.27
Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl (2007) 1.27
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation (2004) 1.27
Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int (2006) 1.25
Impact of biliary complications in right lobe living donor liver transplantation. Transpl Int (2006) 1.23
Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant (2005) 1.22
Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer (2002) 1.22
Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg (2008) 1.22
Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology (2006) 1.22
The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology (2009) 1.21
Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation (2011) 1.18
The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant (2005) 1.16
Plasma disappearance rate of indocyanine green: a tool to evaluate early graft outcome after liver transplantation. Liver Transpl (2009) 1.15
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int (2007) 1.15
Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol (2013) 1.15
The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. Ann Surg (2004) 1.14
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation (2015) 1.13
Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. Hepatology (2007) 1.10
Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl (2005) 1.10